Phillip Woodworth, MD and Jay N. Yepuri, MD, MS, FACG
This program is sponsored by Castle Biosciences.
Recent AGA guidelines recognized a subset of patients with NDBE that progress at a rate similar to higher grades of dysplasia. Clinical case discussions of how to identify high risk patients using a personalized, precision medicine prognostic assay to prevent progression to HGD/EAC. This program is sponsored by Castle Biosciences.
Open to all in-person ACG 2024 attendees, industry-sponsored product theater events provide additional educational opportunities. These programs are independent of the ACG 2024 Annual Scientific Meeting and Postgraduate Course programs. No CME is provided for Exhibitor Product Theater presentations.